Deutsche Bank AG Makes New $2.31 Million Investment in LeMaitre Vascular, Inc. $LMAT

Deutsche Bank AG acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 24,080 shares of the medical instruments supplier’s stock, valued at approximately $2,311,000.

Several other hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada raised its position in shares of LeMaitre Vascular by 1.5% in the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after buying an additional 1,735 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after acquiring an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LeMaitre Vascular by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after acquiring an additional 539 shares during the last quarter. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after acquiring an additional 115,141 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in LeMaitre Vascular by 27.0% during the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Citizens Jmp raised their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular has an average rating of “Hold” and a consensus target price of $110.60.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $79.67 on Friday. LeMaitre Vascular, Inc. has a 1 year low of $78.27 and a 1 year high of $118.01. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of 27.95, a price-to-earnings-growth ratio of 2.30 and a beta of 0.53. The business has a 50-day moving average of $93.31 and a 200-day moving average of $99.46.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.60 earnings per share. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio is currently 35.09%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.